Ariatti joins Toshiba as marketing VP
Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at
Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at Otsuka Electronicsand then at Elscint after that company acquired Otsuka last year.
Ariatti rejoins Toshiba after a stint with the vendor beginningin 1989, when he served as director of the CT business unit andlater as director of MRI marketing. He has also worked with PhilipsMedical Systems.
In his new position, Ariatti oversees marketing for Toshiba'sCT, MRI, nuclear medicine, and vascular and general x-ray products,as well as corporate marketing and marketing communications.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
